Houston startups win NASA funding for space tech projects

fresh funding

Houston startups were recently named among the nearly 300 recipients that received a portion of $44.85 million from NASA to develop space technology. Photo via NASA/Ben Smegelsky

Three Houston startups were granted awards from NASA this month to develop new technologies for the space agency.

The companies are among nearly 300 recipients that received a total agency investment of $44.85 million through the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Phase I grant programs, according to NASA.

Each selected company will receive $150,000 and, based on their progress, will be eligible to submit proposals for up to $850,000 in Phase II funding to develop prototypes.

The SBIR program lasts for six months and contracts small businesses. The Houston NASA 2025 SBIR awardees include:

Solidec Inc.

  • Principal investigator: Yang Xia
  • Proposal: Highly reliable and energy-efficient electrosynthesis of high-purity hydrogen peroxide from air and water in a nanobubble facilitated porous solid electrolyte reactor

Rarefied Studios LLC

  • Principal investigator: Kyle Higdon
  • Proposal: Plume impingement module for autonomous proximity operations

The STTR program contracts small businesses in partnership with a research institution and lasts for 13 months. The Houston NASA 2025 STTR awardees include:

Affekta LLC

  • Principal investigator: Hedinn Steingrimsson
  • Proposal: Verifiable success in handling unknown unknowns in space habitat simulations and a cyber-physical system

Solidec and Affekta have ties to Rice University.

Solidec extracts molecules from water and air, then transforms them into pure chemicals and fuels that are free of carbon emissions. It was co-founded by Rice professor Haotian Wang and and was an Innovation Fellow at Rice’s Liu Idea Lab for Innovation and Entrepreneurship. It was previouslt selected for Chevron Technology Ventures’ catalyst program, a Rice One Small Step grant, a U.S. Department of Energy grant, and the first cohort of the Activate Houston program.

Affekta, an AI course, AI assistance and e-learning platform, was a part of Rice's OwlSpark in 2023.

From Your Site Articles
Venus Aerospace successfully completed the flight test of its hypersonic engine, the first of an American-developed engine of its kind. Photo courtesy Venus Aerospace

Houston aerospace co. soars with first U.S. test flight of hypersonic engine

taking off

Houston-based Venus Aerospace successfully completed the first U.S. flight test of its proprietary engine at a demonstration at Spaceport America in New Mexico.

Venus’ next-generation rotating detonation rocket engine (RDRE) is supported by a $155,908 federal Small Business Innovation Research (SBIR) grant from NASA and aims to enable vehicles to travel four to six times the speed of sound from a conventional runway. The recent flight test was the first of an American-developed engine of its kind.

"With this flight test, Venus Aerospace is transforming a decades-old engineering challenge into an operational reality,” Thomas d'Halluin, managing partner at Airbus Ventures, an investor in Venus, said in a news release. “Getting a rotating detonation engine integrated, launch-ready, and validated under real conditions is no small feat. Venus has shown an extraordinary ability to translate deep technical insight into hardware progress, and we're proud to support their bold approach in their attempt to unlock the hypersonic economy and forge the future of propulsion."

Venus’ RDRE operates through supersonic shockwaves, called detonations, that generate more power with less fuel. It is designed to be affordable and scalable for defense and commercial systems.

The RDRE is also engineered to work with the company's air-breathing detonation ramjet, the VDR2, which helps enable aircraft to take off from a runway and transition to speeds exceeding Mach 6. Venus plans for full-scale propulsion testing and vehicle integration of this system. Venus’ ultimate goal is to develop a Mach 4 reusable passenger aircraft, known as the Stargazer M4.

"This milestone proves our engine works outside the lab, under real flight conditions," Andrew Duggleby, Venus co-founder and chief technology officer, said in the release. "Rotating detonation has been a long-sought gain in performance. Venus' RDRE solved the last but critical steps to harness the theoretical benefits of pressure gain combustion. We've built an engine that not only runs, but runs reliably and efficiently—and that's what makes it scalable. This is the foundation we need that, combined with a ramjet, completes the system from take-off to sustained hypersonic flight."

The hypersonic market is projected to surpass $12 billion by 2030, according to Venus.

"This is the moment we've been working toward for five years," Sassie Duggleby, CEO and co-founder of Venus Aerospace, added in the release. "We've proven that this technology works—not just in simulations or the lab, but in the air. With this milestone, we're one step closer to making high-speed flight accessible, affordable, and sustainable."

Venus Aerospace has used a Small Business Innovation Research (SBIR) grant from NASA to develop new features of its compact rocket engine for hypersonic flights. Photo courtesy of Venus Aerospace.

Houston space tech company develops new hypersonic engine features with NASA funding

testing 1, 2, 3

Outfitted with a new type of aerospace technology, a rocket engine developed by Houston startup Venus Aerospace for hypersonic flights will undergo testing this summer.

Supported by a $155,908 federal Small Business Innovation Research (SBIR) grant from NASA, Venus Aerospace came up with a new design for nozzles — engine parts that help manage power — for its compact rocket engine. Venus Aerospace says the newly configured nozzles have “exceeded expectations” and will be incorporated into Venus’ upcoming ground-based engine testing.

“We’ve already proven our engine outperforms traditional systems on both efficiency and size,” Venus Aerospace CEO Sassie Duggleby says. “The technology we developed with NASA’s support will now be part of our integrated engine platform — bringing us one step closer to proving that efficient, compact, and affordable hypersonic flight can be scaled.”

The engine at the heart of Venus’ flight platform is called a rotating detonation rocket engine (RDRE). Venus says it’s the first U.S. company to make a scalable, affordable, flight-ready RDRE.

Unlike conventional rocket engines, Venus’ RDRE operates through supersonic shockwaves, called detonations, that generate more power with less fuel.

“This is just the beginning of what can be achieved with Venus propulsion technology,” says Andrew Duggleby, chief technology officer at Venus, founded in 2020. “We’ve built a compact high-performance system that unlocks speed, range, and agility across aerospace, defense, and many other applications. And we’re confident in its readiness for flight.”

Last fall, the company unveiled a high-speed engine system that enables takeoff, acceleration, and hypersonic cruising — all powered by a single engine. While most high-speed systems require multiple engines to operate at different speeds, Venus’ innovation does away with the cost, weight and complexity of traditional propulsion technology.

Among other applications, the Venus system supports:

  • Spacecraft landers
  • Low-earth-orbit satellites
  • Vehicles that haul space cargo
  • Hypersonic drones and missiles
VenoStent has raised additional funding. Image courtesy of VenoStent

Houston health tech startup secures $20M series A, NIH grant amid clinical trials

fresh funding

A clinical-stage Houston health tech company with a novel therapeutic device has raised venture capital funding and secured a grant from the National Institutes of Health.

VenoStent Inc., which is currently in clinical trials with its bioabsorbable perivascular wrap, announced the closing of a $20 million series A round co-led by Good Growth Capital and IAG Capital Partners. The two Charleston, South Carolina-based firms also led VenoStent's 2023 series A round that closed last year at $16 million.

Additionally, the company secured a $3.6 million Small Business Innovation Research (SBIR) Phase II Grant from NIH, which will help fund its multi-center, 200-patient, randomized controlled trial in the United States.

Tim Boire, VenoStent CEO and co-founder, describes 2024 so far as "a momentous year" so far for his company.

"In the span of a few months, we initiated our first clinical sites, enrolled the first patients in our large RCT and closed our Series A with Norwest," Boire says in a news release. "We also received the NIH grant, which enables us to execute our trial with the highest degree of quality and rigor to make it as scientifically robust and impactful to patients as possible.

'Each of these are major company milestones that collectively represent many years of intensive and fruitful R&D and collaboration," he continues. "These recent milestones will propel our company forward to an exciting next phase."

Tim Boire is the CEO and co-founder of VenoStent. Photo via LinkedIn

The company's innovation, the SelfWrap, goes around arteriovenous (AV) access sites at the time of AV fistula creation surgery. The device is intended "to accelerate the usability and increase the durability of the fistula sites for chronic kidney disease (CKD) patients requiring hemodialysis," reads the release, "mimicking the arterial environment in veins, which experience a 10x increase in pressure and flow during AV creation and causes the veins to become unusable in dialysis."

Along with the investment, VenoStent announced two new board observers. Norwest General Partner Dr. Zack Scott and Investor Dr. Ehi Akhirome are bringing their expertise to the growing company.

"Norwest's investment is tremendous validation for VenoStent, and we are thrilled to have both Zack and Ehi joining the company's board," VenoStent COO and Co-Founder Geoffrey Lucks adds in the release. "Zack and Ehi have extensive knowledge in our space, and their added value will match the capital and cache of Norwest dollar-for-dollar."

Last year at the same time VenoStent announced its last funding round, the SelfWrap was approved by the U.S. Food and Drug Administration to begin its U.S. Investigational Device Exemption (IDE) study.

"Over half a million people in the U.S. rely on hemodialysis to survive and require an arteriovenous fistula creation surgery in order to receive the treatment. However, the AV fistula procedure has a one-year failure rate of more than 60 percent, which significantly impacts patients' survival rates and quality of life," Scott says in the release. "VenoStent's groundbreaking technology for AV fistula formation, SelfWrap, has the potential to significantly improve these odds. We look forward to working with the VenoStent team as it proves the efficacy of this breakthrough technology in order to improve the lives of hundreds of thousands of CKD patients."

Last summer, Boire told InnovationMap on the Houston Innovators Podcast that he's looking to launch the product in 2026.

Houston-area Ad Astra Rocket Company, which is working on a technology that could increase the speed of space travel, received fresh funding from NASA. Photo via NASA.gov

NASA doles out $98M in funding to small business innovators, including 6 Texas firms

grants lifting off

Almost 100 small businesses with aerospace technology received the greenlight from NASA on their proposals for grant funding.

NASA approved 112 proposals from 92 small businesses in April. These businesses will receive a slice of the $98 million Phase II funding from the Small Business Innovation Research program. The early-stage $850,000 SBIR grants allow awardees to build on their success from the program's first phase. The firms will have 24 months to execute on their proposals with the fresh funding.

“These Phase II awards support a breadth of technologies that have the potential to be transformational for so many different projects and missions across NASA,” says Jenn Gustetic, director of early stage innovation and partnerships for NASA's Space Technology Mission Directorate, in a news release. “In addition, it’s important that we’re including the innovative potential of all of America’s small businesses and entrepreneurs, so we’re proud that 28% of these awards are to underrepresented small businesses and 31% are to first time SBIR Phase II awardees."

Six of the award recipients are based in Texas. Here are the companies and their proposal technology:

  • Ad Astra Rocket Company, headquartered in Webster: Improved Thermo-Mechanical Design of the VASIMR RF Coupler
  • Lunar Resources Inc., headquartered in Houston: Ultra-Electrical-Efficient Process to Perform Regolith Additive Manufacturing of Complex Structures
  • Lynntech Inc., headquartered in College Station: Miniaturized Reagent Regenerative Ion Analyzer for Elemental Analysis
  • QED Secure Solutions, headquartered in Coppell: Avionics Intrusion Detection and Attack Identification
  • Stone Aerospace Inc., headquartered in Del Valle: Sediment Sequestration for Hot Water Drilling Cryobots
  • Texas Research Institute Austin Inc., headquartered in Austin: Accelerated Creep Test Methodologies for Space Habitat Softgood Structural Materials

The Ad Astra Rocket Company's technology, the Variable Specific Impulse Magnetoplasma Rocket, or VASIMR, is an electrothermal thruster that, once developed using the grant, would allow for faster space travel.

“Our program has the responsibility of supporting ideas and technologies that will have impact on NASA’s work and have strong commercial potential,” says Jason L. Kessler, program executive for NASA's SBIR and Small Business Technology Transfer program, in the release. “We're always excited when we can find technologies that help our agency's missions while also having direct benefits for all."

NASA's SBIR program, which takes no equity, offers up to $1 million to selected business during the first three years. Post Phase II opportunities include up to nearly $3 million in funding. The program is a part of NASA's Space Technology Mission Directorate and managed by NASA’s Ames Research Center in California's Silicon Valley.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston geothermal unicorn Fervo officially files for IPO

going public

Fervo Energy has officially filed for IPO.

The Houston-based geothermal unicorn filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission on April 17 to list its Class A common stock on the Nasdaq exchange. Fervo intends to be listed under the ticker symbol "FRVO."

The number and price of the shares have not yet been determined, according to a news release from Fervo. J.P. Morgan, BofA Securities, RBC Capital Markets and Barclays are leading the offering.

The highly anticipated filing comes as Fervo readies its flagship Cape Station geothermal project to deliver its first power later this year

"Today, miles-long lines for gasoline have been replaced by lines for electricity. Tech companies compete for megawatts to claim AI market share. Manufacturers jockey for power to strengthen American industry. Utilities demand clean, firm electricity to stabilize the grid," Fervo CEO Tim Latimer shared in the filing. "Fervo is prepared to serve all of these customers. Not with complex, idiosyncratic projects but with a simplified, standardized product capable of delivering around-the-clock, carbon-free power using proven oil and gas technology."

Fervo has been preparing to file for IPO for months. Axios Pro first reported that the company "quietly" filed for an IPO in January and estimated it would be valued between $2 billion and $3 billion.

Fervo also closed $421 million in non-recourse debt financing for the first phase of Cape Station last month and raised a $462 million Series E in December. The company also announced the addition of four heavyweights to its board of directors last week, including Meg Whitman, former CEO of eBay, Hewlett-Packard, and Spring-based HPE.

Fervo reported a net loss of $70.5 million for the 2025 fiscal year in the S-1 filing and a loss of $41.1 million in 2024.

Tracxn.com estimates that Fervo has raised $1.12 billion over 12 funding rounds. The company was founded in 2017 by Latimer and CTO Jack Norbeck.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

New UT Austin med center, anchored by MD Anderson, gets $1 billion gift

Future of Health

A donation announced Tuesday, April 21, breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release.

The release also records "significant support" for undergraduate scholarships, student housing, and the Texas Advanced Computing Center for supercomputing research.

Both the new research campus and the UT Dell Medical Center will integrate advanced computing into their research and practices. At the medical center, the university hopes that will lead to "earlier detection, more precise and personalized care, and better health outcomes." The University of Texas MD Anderson Cancer Center will also be integrated into the new medical center.

That comes with a numeric goal measured in 10s: raise $10 billion and rank among the top 10 medical centers in the U.S., both in the next decade.

In the shorter term, the university will break ground on the medical center with architecture firm Skidmore, Owings & Merrill (SOM) "later this year."

“UT Austin, where Dell Technologies was founded from a dorm room, has always been a place where bold ideas become real-world impact,” said Michael and Susan Dell in a joint statement.

They continued, “What makes this moment so meaningful is the opportunity to build something that brings every part of the journey together — from how students learn, to how discoveries are made, to how care reaches families. By bringing together medicine, science and computing in one campus designed for the AI era, UT can create more opportunity, deliver better outcomes, and build a stronger future for communities across Texas and beyond.”

This is the second major gift this year for the planned multibillion-dollar medical center. In January, Tench Coxe, a former venture capitalist who’s a major shareholder in chipmaking giant Nvidia, and Simone Coxe, co-founder and former CEO of the Blanc & Otus PR firm, contributed $100 million$100 million.

Baylor scientist lands $2M grant to explore links between viruses and Alzheimer’s

Alzheimer’s research

A Baylor College of Medicine scientist will begin exploring the possible link between Alzheimer’s disease and viral infections thanks to a $2 million grant awarded in March.

Dr. Ryan S. Dhindsa is an assistant professor of pathology & immunology at Baylor and a principal investigator at Texas Children’s Duncan Neurological Research Institute (Duncan NRI). He hypothesizes that Alzheimer’s may have some link to previous viral infections contracted by the patient. To study this intriguing possibility, the American Brain Foundation has gifted him the Cure One, Cure Many award in neuroinflammation.

“It is an honor to receive this support from the Cure One, Cure Many Award. Viral infections are emerging as a major, underappreciated driver of Alzheimer's disease, and this award will allow our team to conduct the most comprehensive screen of viral exposures and host genetics in Alzheimer's to date, spanning over a million individuals,” Dhindsa said in a news release. “Our goal is to identify which viruses matter most, why some people are more vulnerable than others, and ultimately move the field closer to new therapeutic strategies for patients.”

Roughly 150 million people worldwide will suffer from Alzheimer’s by 2050, making it the most common cause of dementia in the world. Despite this, scientists are still at a loss as to what exactly causes it.

Dhindsa’s research is part of a new range of theories that certain viral infections may trigger Alzheimer’s. His team will take a two-fold approach. First, they will analyze the medical records of more than a million individuals looking for patterns. Second, they will analyze viral DNA in stem cell-derived brain cells to see how the infections could contribute to neurological decay. The scale of the genomic data gathering is unprecedented and may highlight a link that traditional studies have missed.

Also joining the project are Dr. Caleb Lareau of Memorial Sloan Kettering Cancer Center and Dr. Artem Babaian of the University of Toronto. Should a link be found, it would open the door to using anti-virals to prevent or treat Alzheimer’s.

View All Listings